#USA #Denver #EmVenio Clinical Research #PCM Trials #Clinical Trial Service

EmVenio Clinical Research: A New Era in Clinical Trials

In a significant move to streamline and enhance clinical trial accessibility, PCM Trials, along with its subsidiaries EmVenio Research and Clinical Trial Service, has rebranded itself as EmVenio Clinical Research. This rebranding aligns three innovative organizations under a single banner, aiming to set a new industry standard for the reach and efficiency of community clinical research.

Greg Austin, the president of PCM Trials and now president of EmVenio Clinical Research, stated, "By uniting three strong companies, we establish a new benchmark in the industry for the reach and accessibility of clinical trials." This consolidation allows for greater flexibility and a more extensive global presence, enabling sponsors and contract research organizations to engage with patients more effectively.

As a division of Professional Case Management, EmVenio Clinical Research benefits from a solid foundation of clinical expertise and compassionate care. With operations in over 80 countries, EmVenio is leveraging local research sites and mobile teams to meet potential participants where they are, whether at home or in their communities.

New Services and Innovations

One of the key launches accompanying this rebranding is the introduction of Patient Navigator™, a tailored support service designed to mitigate logistical and financial barriers to clinical trial participation. This offering is especially crucial in therapeutic areas where participation can be particularly burdensome, such as rare diseases and pediatrics.

Patient Navigator™ aims to enhance patient retention and minimize dropout rates by providing coordinated assistance, including travel arrangements, accommodation, and reimbursement options. In addition to this, EmVenio offers remote and virtual visit capabilities, providing flexible solutions to meet patient needs.

The founder of PCM Trials, established in 2008, has long been recognized for innovating decentralized clinical trials with specialized mobile nurse visits at participants’ homes. Many of the innovations from PCM Trials have become standard practices within the clinical research landscape. Following the acquisition of Clinical Trials Service in 2024 and EmVenio Research shortly thereafter, a powerful alliance has formed to broaden global access to clinical trials.

Promoting Inclusion and Diversity

The merger not only aims at enhancing reach but also emphasizes inclusivity in clinical research. EmVenio Clinical Research has successfully recruited over 75% of patients from minority backgrounds and has managed to retain more than 92% of trial participants, reflecting its commitment to represent diverse populations in clinical studies.

Austin highlights that the name EmVenio combines "empower" and the Latin word "venio," meaning "to reach." This encapsulates the unified team's vision for the future of research—one that makes clinical studies accessible to all segments of the population that traditional methods often overlook.

A Promising Future

With a workforce of approximately 5,000 professionals dedicated to clinical trials across 80 countries, EmVenio Clinical Research is positioned to deliver high-quality studies efficiently and on a large scale. Its community-based sites and mobile services make trials more accessible to patients, aiming to produce clean, reliable data and consistent outcomes. EmVenio emphasizes empathy and collaboration, stating that true progress in research happens when the data collected reflects the real world.

For more information on EmVenio Clinical Research’s services and initiatives, visit their official website at emvenio.com.